DiscoverThe Genetics Podcast
The Genetics Podcast
Claim Ownership

The Genetics Podcast

Author: Sano Genetics

Subscribed: 342Played: 4,928
Share

Description

Exploring all things genetics. Dr Patrick Short, University of Cambridge alumnus and CEO of Sano Genetics, analyses the science, interviews the experts, and discusses the latest findings and breakthroughs in genetic research. To find out more about Sano Genetics and its mission to accelerate the future of precision medicine visit: www.sanogenetics.com
265 Episodes
Reverse
This week on The Genetics Podcast, Patrick is joined by Dr. Joe Volpe, Executive Director, Scientific Strategy & Commercialization at Labcorp. They discuss how blood biomarkers like p-tau217 are changing Alzheimer’s diagnosis, which biomarkers are emerging in Parkinson’s disease and ALS, and what Labcorp’s real-world testing data reveals about how physicians use these tests.Show Notes0:00 Intro to The Genetics Podcast00:58 Welcome to Joe 01:47 Joe’s career in HIV genetics and his move into neurology06:35 Alzheimer’s blood biomarkers, beta amyloid, and the rise of p-tau21711:04 Why p-tau217 works as a scalable Alzheimer’s blood test12:35 How p-tau217 triages patients and what it can’t tell clinicians14:08 APOE testing demand and why it predicts risk without being definitive17:46 Where Alzheimer’s treatment and early detection go next, and what is still unknown21:26 How Parkinson’s and ALS diagnostics are following the path Alzheimer’s took24:09 Neurofilament light (NfL), peripherin, and DDC as emerging ALS and Parkinson’s biomarkers27:04 Where DDC fits in Parkinson’s diagnosis compared with p-tau21729:30 How Labcorp’s real-world testing data shows what NfL and p-tau217 are used for34:27 How Labcorp decides which neurology biomarkers to launch and when38:12 Future potential for migraine biomarkers that can guide treatment choices41:07 Closing remarks
This week on The Genetics Podcast, Patrick goes solo to look at what recent AI breakthroughs in mathematics could mean for biology. He discusses the OpenAI results on the Navier-Stokes equation and hundreds of open math problems, what makes math and code so easy for AI to improve on, how self-driving labs and surrogate endpoints could speed up drug development, and where the biggest gaps and opportunities remain.Show Notes0:00 Intro to The Genetics Podcast00:58 What the OpenAI math breakthroughs could mean for biology02:57 AI’s recent frontier math results and how mathematicians reacted09:12 Lean as a proof checker and why it matters for math10:44 Four conditions behind AI’s math progress and how biology compares16:22 Why verification speed decides where AI can accelerate biology19:35 How lab automation shortens feedback loops for variants and antibodies23:13 How validated biomarkers let early trials predict clinical outcomes26:11 Why validated surrogate endpoints could speed up drug development31:58 How startups and big pharma are building self-driving labs33:40 Virtual cell models built from perturbation data34:50 Genetics-driven drug discovery and the Phase II success rate question37:42 Verification speed and surrogate endpoints as biology’s biggest gaps40:38 Closing remarks
This week on The Genetics Podcast, Patrick is joined by Dr. Sek Kathiresan, CEO of Verve Therapeutics and SVP, Head of Obesity Research and Early Development at Eli Lilly. They discuss how protective genetic variants led to the development of a one-time gene editing therapy for heart disease in the face of early doubt, the phase one results for Verve-102, what recent trial failures mean for genetic target validation, and the unmet needs in obesity treatment.Show Notes0:00 Intro to The Genetics Podcast00:59 Welcome to Sek 01:40 Sek’s family history of heart disease and how it motivated him to pursue cardio therapeutics03:29 Sek’s background and research on the genetics of coronary artery disease and protective mutations08:03 Reactions to the Verve launch and the biological, technological, regulatory, and commercial risks11:00 Verve-102 phase one results and the case for lifelong LDL lowering16:14 Why cumulative exposure means lowering LDL earlier and for longer17:53 Recent trial failures in genetically validated targets and what the Lp(a) trial leaves unanswered20:33 Polygenic risk scores and who benefits most from LDL lowering23:36 Sek’s new role at Lilly and the remaining unmet needs in obesity treatment29:06 Whether one-time gene therapy could work for obesity and how GLP-1 drugs drive weight loss30:38 Food intake, energy expenditure, and the search for new obesity mechanisms32:15 Why Lilly is investing so heavily in genetic medicine34:35 Closing remarksFind out moreANGPTL3 study in NEJM (https://pmc.ncbi.nlm.nih.gov/articles/PMC3008575/)Verve-102 study (https://www.nejm.org/doi/10.1056/NEJMoa2601283)
This week on The Genetics Podcast, Patrick is joined by Dr. Luke Pilling, Senior Lecturer in Genetic Epidemiology at the University of Exeter. They discuss hemochromatosis and the case for earlier diagnosis, and the genetic drivers of multimorbidity, pharmacogenetics, and drug response.Show Notes0:00 Intro to The Genetics Podcast00:59 Welcome to Luke 01:37 An overview of HFE hemochromatosis and why diagnosis is delayed 04:24 Iron levels and overload risk in heterozygous and compound heterozygous carriers05:51 Aging-related effects seen in homozygotes 06:43 How hemochromatosis is currently diagnosed and detected in the UK09:26 Future screening and case finding, including the Our Future Health cohort11:28 Genetic and environmental factors that shape outcomes in C282Y homozygotes 13:28 The GEMINI project and the genetic drivers of multimorbidity15:56 Drug targets from multimorbidity genetics, including repurposing and opposite effects18:49 Using disease sequences in health records to look for earlier intervention points in multimorbidity21:21 Data gaps limiting multimorbidity research, from primary care records to proteomics23:17 Handling misdiagnosis and clinical code accuracy in health record research24:55 International collaborations and the need for more diverse biobank data26:08 Pharmacogenetics research and how genetic variants shape drug response29:04 Limited clinical examples of pharmacogenetics and lessons from non-responders33:08 Genetics of lifespan and healthy aging, and why geroscience pathways rarely appear in GWAS36:06 Luke’s future research focuses 40:39 Closing remarksFind out more:- Hereditary hemochromatosis study- Multimorbidity study- Pharmacogenetics framework study
This week on The Genetics Podcast, Patrick is joined by Dr. James Zou, Associate Professor of Biomedical Data Science at Stanford University. They discuss the concept of virtual biotechs and how AI agents link single cell data to clinical trial success, Paper to Agent and turning papers into living virtual authors, clinical AI from EchoNet to SleepFM, and the role of academia alongside big AI labs.Show Notes0:00 Intro to The Genetics Podcast00:59 Welcome to James 01:55 An overview of James’s virtual biotech and its AI scientist agents04:11 How single cell evidence behind drug targets predicts clinical trial success06:33 Behind the scenes of how autonomous the virtual biotech agents are08:06 Missing proprietary trial data as the next gap for the virtual biotech09:44 Scaling the number of collaborating AI agents as a new frontier for drug discovery12:29 How teamwork and structure evolved among the agents 15:53 Behind the idea of Paper to Agent and virtual authors19:01 What converting over 100 papers into agents revealed about reproducibility23:14 The story behind EchoNet, an FDA-cleared AI tool for cardiac ultrasound26:28 Predicting risk for over 100 future diseases from one night of sleep27:40 Transferring SleepFM from sleep labs to consumer wearables28:43 Combining multimodal health data to predict disease30:10 Longitudinal blood proteomics as the biggest data gap for health AI31:18 The role of academia as an open, neutral counterweight to big AI labs32:51 How James’s path from Cambridge math and Harvard machine learning led to biology34:41 Closing remarksFind out moreVirtual biotech paper (https://www.science.org/doi/10.1126/science.aeg6779)Paper2Agent paper (https://www.nature.com/articles/s41586-026-11044-y)
loading
Comments